Business Wire

FDA Approves Baxter’s RIXUBIS as First Recombinant Factor IX Treatment for Routine Prophylaxis of Hemophilia B

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved RIXUBIS [Coagulation Factor IX ...
News Medical

Baxter to develop recombinant Factor IX proteins to treat hemophilia B

Baxter International Inc. has announced that it has initiated pre-clinical programs to develop recombinant Factor IX proteins to treat hemophilia B. Baxter will develop both an unmodified recombinant ...
Business Wire

Baxter Announces Collaboration with Chatham Therapeutics for Factor IX Hemophilia B Gene Therapy Treatment

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios ...
Chicago Tribune

Baxter a factor in blood device: Genentech…

Baxter a factor in blood device: Genentech Inc. and Baxter Healthcare Corp. said they’re working on an implantable device to help control bleeding in hemophiliacs. The therapy involves a device ...
Chicago Tribune

Baxter buying Wyeth drug unit

Baxter International Inc. will pay $305 million to acquire drugmaker Wyeth’s ESI Lederle generic injectable pharmaceuticals business, a move the Deerfield health-care giant said makes “a great ...
FierceBiotech

FDA Approves Baxter's RIXUBIS as First Recombinant Factor IX Treatment for Routine Prophylaxis of Hemophilia B

Approval brings patients first new rFIX treatment option in more than 15 years DEERFIELD, Ill.--June 27, 2013--Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug ...